Legal & General Group Plc Has $719,000 Position in Replimune Group, Inc. (NASDAQ:REPL)

Legal & General Group Plc grew its position in shares of Replimune Group, Inc. (NASDAQ:REPL) by 42.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 59,366 shares of the company’s stock after purchasing an additional 17,597 shares during the quarter. Legal & General Group Plc owned approximately 0.09% of Replimune Group worth $719,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in REPL. Aster Capital Management DIFC Ltd grew its holdings in Replimune Group by 8,798.9% during the 4th quarter. Aster Capital Management DIFC Ltd now owns 8,276 shares of the company’s stock worth $100,000 after acquiring an additional 8,183 shares during the last quarter. Sei Investments Co. acquired a new position in shares of Replimune Group during the fourth quarter worth $148,000. KLP Kapitalforvaltning AS acquired a new stake in Replimune Group in the fourth quarter valued at $150,000. Arizona State Retirement System bought a new position in Replimune Group during the 4th quarter worth $156,000. Finally, Teacher Retirement System of Texas acquired a new position in Replimune Group during the 4th quarter worth about $189,000. 92.53% of the stock is currently owned by institutional investors.

Replimune Group Stock Up 2.4 %

Shares of NASDAQ REPL opened at $9.27 on Tuesday. The company has a debt-to-equity ratio of 0.14, a current ratio of 11.43 and a quick ratio of 11.43. Replimune Group, Inc. has a 1 year low of $4.92 and a 1 year high of $17.00. The stock has a market capitalization of $713.93 million, a P/E ratio of -3.02 and a beta of 1.26. The company has a 50-day moving average price of $10.15 and a 200-day moving average price of $11.65.

Replimune Group (NASDAQ:REPL) last posted its earnings results on Wednesday, February 12th. The company reported ($0.79) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.09). On average, equities research analysts forecast that Replimune Group, Inc. will post -2.97 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have weighed in on REPL shares. HC Wainwright increased their target price on shares of Replimune Group from $21.00 to $22.00 and gave the company a “buy” rating in a research report on Thursday, February 13th. JPMorgan Chase & Co. raised their price objective on shares of Replimune Group from $16.00 to $18.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 26th. Finally, BMO Capital Markets increased their target price on shares of Replimune Group from $18.00 to $27.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 22nd. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $19.43.

Replimune Group Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.